[Optimization of the medical treatment for acromegaly].

[1]  J. Dieleman,et al.  Risk of Cardiac Valve Regurgitation with Dopamine Agonist use in Parkinson’s Disease and Hyperprolactinaemia , 2012, Drug Safety.

[2]  S. Melmed,et al.  Somatostatin analogs and chimeric somatostatin–dopamine molecules differentially regulate human growth hormone and prolactin gene expression and secretion in vitro , 2012, Molecular and Cellular Endocrinology.

[3]  M. Fleseriu,et al.  Pasireotide LAR is significantly more effective than octreotide LAR at inducing biochemical control in patients with acromegaly: results of a 12-month randomized, double-blind, multicenter, Phase III study , 2012 .

[4]  S. Melmed,et al.  Oral octreotide absorption in human subjects: comparable pharmacokinetics to parenteral octreotide and effective growth hormone suppression. , 2012, The Journal of clinical endocrinology and metabolism.

[5]  M. Buchfelder,et al.  Long-term safety of pegvisomant in patients with acromegaly: comprehensive review of 1288 subjects in ACROSTUDY. , 2012, The Journal of clinical endocrinology and metabolism.

[6]  W. Drake,et al.  Effective combination treatment with cabergoline and low-dose pegvisomant in active acromegaly: a prospective clinical trial. , 2012, The Journal of clinical endocrinology and metabolism.

[7]  S. Ezzat,et al.  American Association of Clinical Endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of acromegaly--2011 update. , 2011, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[8]  A. J. van der Lely,et al.  Combination treatment with somatostatin analogues and pegvisomant in acromegaly. , 2011, Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society.

[9]  H. Orskov,et al.  Cotreatment with pegvisomant and a somatostatin analog (SA) in SA-responsive acromegalic patients. , 2011, The Journal of clinical endocrinology and metabolism.

[10]  A. Colao,et al.  Resistance to somatostatin analogs in acromegaly. , 2011, Endocrine reviews.

[11]  S. Cannavò,et al.  Effects of high-dose octreotide LAR on glucose metabolism in patients with acromegaly inadequately controlled by conventional somatostatin analog therapy. , 2011, European journal of endocrinology.

[12]  P. Chanson,et al.  Place of cabergoline in acromegaly: a meta-analysis. , 2011, The Journal of clinical endocrinology and metabolism.

[13]  K. Badenhoop,et al.  Efficacy and acceptability of lanreotide Autogel® 120 mg at different dose intervals in patients with acromegaly previously treated with octreotide LAR. , 2010, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.

[14]  J. Kopchick,et al.  Hypothesis: Extra-hepatic acromegaly: a new paradigm? , 2011, European journal of endocrinology.

[15]  L. Vilar,et al.  Role of the addition of cabergoline to the management of acromegalic patients resistant to longterm treatment with octreotide LAR , 2011, Pituitary.

[16]  S. Ezzat,et al.  A randomized, controlled, multicentre trial comparing pegvisomant alone with combination therapy of pegvisomant and long‐acting octreotide in patients with acromegaly , 2009, Clinical endocrinology.

[17]  S. Cannavò,et al.  High-dose intramuscular octreotide in patients with acromegaly inadequately controlled on conventional somatostatin analogue therapy: a randomised controlled trial. , 2009, European journal of endocrinology.

[18]  P. Chanson,et al.  Guidelines for acromegaly management: an update. , 2009, The Journal of clinical endocrinology and metabolism.

[19]  A. J. van der Lely,et al.  Combined treatment for acromegaly with long-acting somatostatin analogs and pegvisomant: long-term safety for up to 4.5 years (median 2.2 years) of follow-up in 86 patients. , 2009, European journal of endocrinology.

[20]  P. Chanson,et al.  Control of IGF-I levels with titrated dosing of lanreotide Autogel over 48 weeks in patients with acromegaly , 2008, Clinical endocrinology.

[21]  H. Schmid.  Pasireotide (SOM230): Development, mechanism of action and potential applications , 2008, Molecular and Cellular Endocrinology.

[22]  J. Vandenbroucke,et al.  Mortality in acromegaly: a metaanalysis. , 2008, The Journal of clinical endocrinology and metabolism.

[23]  A. Colao,et al.  Beneficial effect of dose escalation of octreotide-LAR as first-line therapy in patients with acromegaly. , 2007, European journal of endocrinology.

[24]  S. Grottoli,et al.  Efficacy of a slow‐release formulation of lanreotide (Autogel® 120 mg) in patients with acromegaly previously treated with octreotide long acting release (LAR): an open, multicentre longitudinal study , 2007, Clinical endocrinology.

[25]  A. J. van der Lely,et al.  Long-term efficacy and safety of combined treatment of somatostatin analogs and pegvisomant in acromegaly. , 2007, The Journal of clinical endocrinology and metabolism.

[26]  S. Melmed.  Medical progress: Acromegaly. , 2006, The New England journal of medicine.

[27]  D. Lüdecke,et al.  Transsphenoidal Microsurgery for Newly Diagnosed Acromegaly: A Personal View after More than 1,000 Operations , 2006, Neuroendocrinology.

[28]  D. Rabinowitz,et al.  Long-acting somatostatin analog therapy of acromegaly: a meta-analysis. , 2005, The Journal of clinical endocrinology and metabolism.

[29]  G. Lasio,et al.  Four-year treatment with octreotide-long-acting repeatable in 110 acromegalic patients: predictive value of short-term results? , 2003, The Journal of clinical endocrinology and metabolism.

[30]  S. Lamberts,et al.  The pathophysiological consequences of somatostatin receptor internalization and resistance. , 2003, Endocrine reviews.

[31]  H. Rodbard,et al.  American Association of Clinical Endocrinologists medical guidelines for clinical practice for the prevention and treatment of postmenopausal osteoporosis: 2001 edition, with selected updates for 2003. , 2003, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[32]  F. Di Salle,et al.  Long‐term effects of lanreotide SR and octreotide LAR® on tumour shrinkage and GH hypersecretion in patients with previously untreated acromegaly , 2002, Clinical endocrinology.

[33]  G. Sassolas,et al.  Comparison of octreotide acetate LAR and lanreotide SR in patients with acromegaly , 2000, Clinical endocrinology.

[34]  P. Iglesias,et al.  Current management of acromegaly , 2000, Expert opinion on pharmacotherapy.

[35]  M. S. Tewart,et al.  Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. , 2000 .

[36]  Díez Jj.  [Lanreotide++: a new therapeutic option in acromegaly]. , 1996 .